Search company, investor...
Co-Formulate company logo



Acquired | Acquired

About Co-Formulate

Co-Formulate, founded in 2007, provides a comprehensive range of formulation development, analytical and regulatory services to clients in the pharmaceutical, consumer healthcare and personal care industries.

Headquarters Location

MediCity Thane Road

Nottingham, England, NG90 6BH,

United Kingdom

+44 (0) 115 7060418

Missing: Co-Formulate's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Co-Formulate's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Co-Formulate News

Quotient Sciences Launches as the New Global Identity for Quotient Clinical

Nov 10, 2017

November 10, 2017 06:24 AM Eastern Standard Time NOTTINGHAM, England--( BUSINESS WIRE )--Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers. With 700 employees and five operating sites across the United States and the United Kingdom, Quotient is focused on delivering a portfolio of innovative services encompassing formulation development, clinical trial and commercial manufacturing, and clinical pharmacology. Quotient’s Translational Pharmaceutics ® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs. “We are excited about the future of Quotient Sciences,” said Mark Egerton, CEO, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.” To learn more about Quotient Sciences, stop by booth #1443 for the unveiling event at the 2017 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists ( AAPS ) at 10.30am PST on Monday 13 November, in San Diego, California. Meet Quotient’s scientific leadership team and find out how Translational Pharmaceutics works to accelerate the speed of science. ENDS

Co-Formulate Frequently Asked Questions (FAQ)

  • Where is Co-Formulate's headquarters?

    Co-Formulate's headquarters is located at MediCity, Nottingham.

  • What is Co-Formulate's latest funding round?

    Co-Formulate's latest funding round is Acquired.

  • Who are the investors of Co-Formulate?

    Investors of Co-Formulate include Quotient Clinical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.